Gilead Sciences stock reports growth at EUR 133.42, plus 0.02 percent

Published on 09/30/2026 at 14:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences reported USD 7.80 billion in second-quarter revenue against USD 7.40 billion consensus. Lang & Schwarz priced the stock at EUR 133.42, plus 0.02 percent, on September 30, 2026.

Photorealistischer Biotech-Campus von Gilead Sciences mit Glaslabor und Wissenschaftlern — Gilead Sciences Forschungscampus mit ISIN US3755581036 modernes Biopharma-Labor Kalifornien Glasfassade Wissenschaftler arbeiten, Illustration mit AI erstellt.

Gilead Sciences stock (ISIN US3755581036) was trading at EUR 133.42 at Lang & Schwarz on September 30, 2026 at 2:33 p.m. CEST, plus 0.02 percent versus the prior close of EUR 133.39. The company reported USD 7.80 billion in second-quarter 2026 revenue, up 10.6 percent year over year, while a September 30 report linked Gilead to a USD 2.5 million federal grant for oral treatments targeting mosquito-borne flaviviruses.

Revenue beat expectations

MarketBeat reported that Gilead's second-quarter adjusted loss was USD 6.75 per share, narrower than the USD 7.25 consensus loss, while revenue reached USD 7.80 billion against USD 7.40 billion expected. The revenue comparison gives the quarterly result its clearest strength, even as the reported earnings figure remained negative.

Zacks said second-quarter HIV product sales rose 12 percent to USD 5.69 billion, including USD 232 million from Yeztugo. The company raised its full-year HIV sales growth guidance to 9-10 percent from 8 percent and projected 2026 product sales of USD 30.10-30.40 billion.

Lenacapavir broadens the story

As Simply Wall St reported on September 30, 2026, Gilead secured a USD 2.5 million federal grant with research partners for oral flavivirus treatments. The development adds an infectious-disease research angle beyond the established HIV franchise, although its commercial value depends on research and regulatory progress.

Gilead also expanded licensing arrangements for investigational once-yearly lenacapavir to cover 120 high-incidence countries, according to its September 16, 2026 release. The program remains investigational, while twice-yearly lenacapavir is already approved in multiple countries for HIV prevention.

Analyst target stays above the quote

MarketBeat said 29 research firms assigned Gilead a Moderate Buy consensus, with an average 12-month price target of USD 158.78. That target is 17.99 percent above the USD 134.60 reference price cited in the report, but it is a separate US-dollar assessment from the euro quotation used here.

For investors, the central tension is clear: HIV sales and forward guidance are expanding, while second-quarter adjusted EPS remained negative USD 6.75. Gilead's valuation story therefore depends on converting pipeline and HIV growth into sustained earnings.

Gilead Sciences stock stays nearly flat

Gilead Sciences stock was trading at EUR 133.42 at Lang & Schwarz on September 30, 2026 at 2:33 p.m. CEST, plus 0.02 percent versus the prior close of EUR 133.39. On Nasdaq, the stock was last at USD 151.28 on September 29, 2026 at 4:00 p.m. EDT.